Pulmonology Medical News about Cystic Fibrosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Continuous vs Thrice-Daily Ceftazidime for Elective Intravenous Antipseudomonal Therapy in Cystic Fibrosis
Infection, 09/22/09

Riethmueller J et al. – The authors conclude that continuous or thrice–daily dosing of intravenous ceftazidime, both combined with once–daily tobramycin, are equally effective application regimens for elective antipseudomonal therapy in clinically stable patients with CF.

<< Previous
Healthcare expenditures for privately insured people with cystic...

Next >>
The Approach to Pseudomonas aeruginosa in Cystic Fibrosis

Diabetes as a Determinant of Mortality in Cystic Fibrosis
Diabetes Care, 11/20/09 Relevance Score: 69%

Vitamin D supplementation for cystic fibrosis
Cochrane Reviews, 10/28/09 Relevance Score: 69%

Genetic Risk Factor for Liver Disease for Patients With Cystic Fibrosis
Gastroenterology, 10/27/09 Relevance Score: 69%

Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial
Inspire, 10/16/09 Relevance Score: 69%

Pulmonary nocardiosis in cystic fibrosis
Journal of Cystic Fibrosis, 10/07/09 Relevance Score: 69%